Investor Relations

Committee Composition

  Audit Nominating and Corporate Governance Compensation
C. Raymond Larkin, Jr. Chairman of the Board Independent Director *   Committee Chair for Nominating and Corporate Governance Committee  
Chairman

Mr. Larkin was appointed as a director in July 2017. He currently serves as a principal of Group Outcome L.L.C., a merchant banking firm concentrating on medical technologies. Prior to Group Outcome, Mr. Larkin was Chairman and CEO at Eunoe Inc., an investigative device for slowing and stopping progression of Alzheimer's disease. From 2001 to 2007, he served as a part-time Venture Partner at Cutlass Capital, a venture capital firm. Prior to that, he was President and Chief Executive Officer of Nellcor Puritan Bennett, Inc., a respiratory products company. Mr. Larkin also held positions of increasing responsibility at Bentley Laboratories/American Hospital Supply from 1976 to 1983. Mr. Larkin currently serves as board chairman of Align Technology, and also served as board chairman of Heartware, Inc. prior to its acquisition by Medtronic, plc. He received his B.S. degree in Industrial Management from LaSalle University and is a former captain in the United States Marine Corps.


Ross Breckenridge, MA BM BCh FRCP Ph Independent Director * Member of Audit Committee   Member of Compensation Committee
Director

Dr. Breckenridge was appointed as a director in January 2015. Dr. Breckenridge is a senior clinical lecturer and Programme Director for the Masters Programme in Clinical and Experimental Medicine at University College London since 2006, a Fellow of the Royal College of Physicians (London) since 2013, and a Consultant Physician at University College London Hospital since 2006. His research focuses on the heart’s response to low levels of oxygen, with an overall aim to identify novel therapeutic targets for cardiac disease. Dr. Breckenridge has provided consultation services to investors in the biotech and healthcare sector since 1998. He is an academic board member of Empower India, and the Cornelia de Lange Society of Great Britain. He obtained his medical degree from Oxford University, followed by his PhD in Developmental Biology at the University of Cambridge and completed his training in Clinical Pharmacology at University College London.


Brian Dovey Independent Director *   Member of Nominating and Corporate Governance Committee Committee Chair for Compensation Committee
Director

Mr. Dovey has served as a director since June 2001, and was elected Chairman of the Board in March 2016. Since 1988, Mr. Dovey has been a partner of Domain Associates, LLC, a private venture capital management firm focused on life sciences, where he has led innovative investments and has established and directed new initiatives such as the collaboration between Domain and RUSNANO. Since joining Domain, he has served on the board of directors of over 35 private and public companies and has been Chairman of five. He currently sits on the board of two public companies:  REVA, and Orexigen Therapeutics. Prior to joining Domain, Mr. Dovey spent six years at Rorer Group, Inc. (now part of Sanofi‑Aventis), a pharmaceutical and medical device company listed on the NYSE. As president of Rorer from 1986 to 1988, he was the primary architect of the company’s strategic shift to pharmaceuticals. Previous to that, he was President of Survival Technology, Inc., a start‑up medical products company. He also held management positions with Howmedica, Inc., Howmet Corporation, and New York Telephone. Mr. Dovey has served as both President and Chairman of the National Venture Capital Association. He is former Chair and currently serves on the Board of Trustees of the Wistar Institute, a non‑profit preclinical biomedical research company. Mr. Dovey serves on the board of directors and is also Chairman at the Center for Venture Education (Kauffman Fellows Program) and on the La Jolla Playhouse Board of Trustees. He was also a former board member of the industry association representing the medical device industry, as well as the association representing consumer pharmaceuticals. He is a trustee emeritus of Germantown Academy and is a former trustee of the University of Pennsylvania School of Nursing and the Burnham Institute for Medical Research. Mr. Dovey received his B.A. in mathematics from Colgate University and his MBA from the Harvard Business School.


Scott Huennekens Independent Director *† Committee Chair for Audit Committee Member of Nominating and Corporate Governance Committee  
Director

Mr. Huennekens was appointed as a director in March 2015. He is currently President and CEO of Verb Surgical, Inc., a collaboration between Alphabet, Inc. (formally Google) and Johnson & Johnson focused on developing a comprehensive robotic surgical solutions platform. Previously, from April 2002 to February 2015, Mr. Huennekens served as President and Chief Executive Officer of Volcano Corporation, a manufacturer of intravascular imaging equipment for coronary and peripheral applications. Prior to 2002, he served as President and Chief Executive Officer of Digirad Corporation, a diagnostic imaging solutions provider, and also held senior positions at Baxter International, Inc. in the Edwards Cardiovascular Division and the Novacor division. Mr. Huennekens currently serves on the boards of EndoChoice and the Medical Device Manufacturers Association (“MDMA”). He received his B.S. in Business Administration from the University of Southern California and an MBA from Harvard Business School.

 


Robert Thomas Independent Director *† Member of Audit Committee   Member of Compensation Committee
Director

Mr. Thomas has served as a director since July 2010. He has also served as a director and non‑executive Chairman of the Board of HeartWare Limited/HeartWare International, Inc., a NASDAQ-listed medical device company, since November 2004. He is currently a director of a number of Australian public companies, including Virgin Australia Limited and Biotron Limited; he is Chairman of Starpharma Limited. Between October 2004 and September 2008, Mr. Thomas was a consultant to Citigroup Corporate and Investment Bank. Between March 2003 and September 2004, he was Chairman of Global Corporate and Investment Bank, Citigroup Global Markets, Australia and New Zealand. Prior to that time, Mr. Thomas was Chief Executive Officer of Citigroup’s Corporate and Investment Bank (formerly known as Salomon Smith Barney), Australia and New Zealand from October 1999 until February 2003. Mr. Thomas is Chairman of Aus Bio Limited, a director of O’Connell Street Associates and Chairman of Grahger Capital Securities. He also is a member of the advisory board of Inteq Limited. Mr. Thomas holds a Bachelor of Economics from Monash University, Australia. He is a member of the Stockbrokers Association of Australia and is a Master Stockbroker. Mr. Thomas is also a Fellow of the Financial Services Institute of Australia and the Australian Institute of Company Directors. He is on the board of the NSW State Library Foundation and serves on NSW State Library’s Audit and Risk Committee.


Chair of the Board = Chair of the Board
Committee Chair = Chair
Committee Member = Member
Independent Director = Independent Director
* = Independent director under SEC standards
† = Independent director under ASX standards